In November 2002, Theravance entered into a collaboration with GlaxoSmithKline plc to develop and commercialize a Long-Acting Beta2 Agonist (LABA) product candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Beta2 agonists are medicines that work by relaxing the muscles that line the bronchial airways, allowing the capacity of the airways to expand (known as bronchodilation) and leading to relief and/or prevention of many of the symptoms of asthma and COPD. These product candidates are intended to be administered via inhalation once daily both as a single new medicine and as part of a new combination medicine with an inhaled corticosteroid.


©2008 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.

Terms of Use     Website Admin Contact     Theravance Contact     Site Map